I appreciated the comments @bedger
I think PAR are going about this the right way. They are tackling two indications that stand a higher than average probability of delivering success: OA and MPS, and while these two indications alone will make PAR a successful company, my interest in PAR lies in their intellectual nous when it comes to repurposing treatments.
This will also be the difference between whether PAR becomes a 10-bagger or a 100-bagger company in my opinion.
Not advice, DYOR, GLTAH
Ann: Half Yearly Report and Accounts, page-20
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.035(12.7%) |
Mkt cap ! $108.4M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 31.0¢ | 27.5¢ | $108.9K | 371.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 17420 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |